Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 – ResearchAndMarkets.com

Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 – ResearchAndMarkets.com




Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Community-Acquired Bacterial Pneumonia (CABP) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Community-Acquired Bacterial Pneumonia (CABP) Drug Chapters

Drug chapter segment of the Community-Acquired Bacterial Pneumonia (CABP) report encloses the detailed analysis of Community-Acquired Bacterial Pneumonia (CABP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Community-Acquired Bacterial Pneumonia (CABP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Community-Acquired Bacterial Pneumonia (CABP) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia (CABP) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Community-Acquired Bacterial Pneumonia (CABP) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Community-Acquired Bacterial Pneumonia (CABP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Community-Acquired Bacterial Pneumonia (CABP) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Community-Acquired Bacterial Pneumonia (CABP) emerging therapies.

Report Highlights

  • In the coming years, Community-Acquired Bacterial Pneumonia (CABP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Community-Acquired Bacterial Pneumonia (CABP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Community-Acquired Bacterial Pneumonia (CABP). Launch of emerging therapies will significantly impact the Community-Acquired Bacterial Pneumonia (CABP) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Community-Acquired Bacterial Pneumonia (CABP)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Community-Acquired Bacterial Pneumonia (CABP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Community-Acquired Bacterial Pneumonia (CABP) Pipeline Analysis
  • Community-Acquired Bacterial Pneumonia (CABP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Community-Acquired Bacterial Pneumonia (CABP) Report Assessment

Current Treatment Practices

  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance

3.1. Market Share (%) Distribution Community-Acquired Bacterial Pneumonia (CABP) in 2019

3.2. Market Share (%) Distribution of Community-Acquired Bacterial Pneumonia (CABP) in 2032

4. Executive Summary of Community-Acquired Bacterial Pneumonia (CABP)

5. Disease Background and Overview

6. Treatment and Management

6.1. Antibiotic therapy

6.2. Diuretics

6.3. Corticosteroids

6.4. Later management

6.5. Diagnostic and Treatment Guidelines

6.5.1. The American Thoracic Society and the Infectious Diseases Society of America

6.5.2. NICE

7. Epidemiology and Patient Population

8. Patient Journey 1

9. Patient Journey 2

10. Marketed Therapies

10.1. Lefamulin (Xenleta): Nabriva Therapeutics

10.2. Delafloxacin – Melinta Therapeutics/Wakunaga Pharmaceutical

10.3. Ceftaroline fosamil (Teflaro): Forest Pharmaceuticals

10.4. Linezolid (Zyvox): Pfizer

10.5. Omadacycline (NUZYRA): Paratek Pharmaceuticals

10.6. Telavancin (Vibativ): Cumberland Pharmaceuticals Inc./Theravance Biopharma

10.7. Ceftolozane/Tazobactam (Zerbaxa): Merck Sharp & Dohme Inc./Cubist Pharmaceuticals LLC

10.8. Imipenem/Cilastatin/Relebactam (RecarbrioT): Merck Sharp and Dohme

10.9. Cefiderocol ( Fetroja): Shionogi Inc.

10.10. Ceftazidime/Avibactam (Avycaz): Allergan/Pfizer

11. Emerging Drugs

11.1. CAL02: Eagle Pharmaceutical Inc/Combioxin SA

11.2. Cx611: Takeda/TiGenix

12. Other Therapies: Generics

12.1. Amoxicillin

12.2. Azithromycin

12.3. Clarithromycin

12.4. Doxycycline

12.5. Moxifloxacin

12.6. Vaccine

12.6.1. Prevnar 13

12.6.2. Vaxneuvance

13. Community-Acquired Bacterial Pneumonia: 7 Major Market Analysis

14. Market Outlook

Companies Mentioned

  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Wakunaga Pharmaceutical
  • Forest Pharmaceuticals
  • Pfizer
  • Paratek Pharmaceuticals
  • Cumberland Pharmaceuticals Inc.
  • Theravance Biopharma
  • Merck Sharp & Dohme Inc.
  • Cubist Pharmaceuticals LLC
  • Shionogi Inc.
  • Allergan
  • Eagle Pharmaceutical Inc
  • Combioxin SA
  • Takeda
  • TiGenix

For more information about this report visit https://www.researchandmarkets.com/r/vtv4k7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900